Clinical trials: ST-Elevation Myocardial Infarction
Heart Failure, Myocardial Infarction
Impact of Intracoronary Injection of Autologous BMMC for LV Contractility and Remodeling in Patients With STEMI
This is multicentre, randomised open-label, controlled, parallel-group phase III study. Its aim is to demonstrate that a triple intracoronary infusion of autologous bone marrow-derived mononuclear cells in addition to state of…
- Trial name
- RACE-STEMI (NCT02323620)
- Testing
- Intracoronary infusion of BM-MC
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- American Heart of Poland
Coronary Artery Disease, Myocardial Infarction
Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients
The purpose of the study it to evaluate whether primary percutaneous coronary intervention (primary PCI) with a new thrombectomy device as compared to primary PCI without thrombectomy increases minimal flow area after stenting…
- Conditions
- Coronary Artery Disease, Myocardial Infarction, STEMI
- Trial name
- TROFI (NCT01271361)
- Testing
- primary PCI with thrombectomy, primary PCI without thrombectomy
- Where
- 5 sites in Denmark, France and 2 more
- Volunteers
- 140 people
- Sponsor
- Terumo Europe N.V.
ST-elevation Myocardial Infarction (STEMI), Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction
Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the age-related expansion of hematopoietic stem cell clones carrying somatic mutations in leukemia-associated driver genes (e.g., DNMT3A, TET2, ASXL1) in the…
- Trial name
- CHIP in STEMI (NCT07615023)
- Testing
- Clonal hematopoiesis assessment and cardiac magnetic resonance imaging
- Where
- Austria
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
STEMI
CMR or Angiography for FFR-guided Revascularisation
Around 50% of patients that present with ST Elevation Myocardial Infarction (STEMI) have residual disease in the non-culprit lesions.
- Trial name
- CRAFT-MI (NCT03408912)
- Testing
- FFR
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Karolinska Institutet
Platelet Reactivity
High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)
This is a prospective, multi-center, non-randomized, controlled study in 2 sequential groups of P2Y12 inhibitor-naive consecutive STEMI patients undergoing primary PCI.
- Trial name
- NCT01835353
- Testing
- Prasugrel 100mg loading dose, Prasugrel 60mg loading dose
- Where
- Greece
- Volunteers
- 82 people
- Sponsor
- University of Patras
Acute Myocardial Infarction
Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients
The aim of this randomized trial is to compare the efficacy of high dose tirofiban administered as either an intracoronary bolus alone or as an intravenous bolus followed by a maintenance infusion with respect to microvascular…
- Trial name
- NCT01109134
- Testing
- tirofiban intracoronary bolus-only, tirofiban intravenous bolus plus infusion
- Volunteers
- 49 people
- Sponsor
- Kosuyolu Heart Hospital
Non-ST Elevation Myocardial Infarction
Initial CT Perfusion-Guided Strategy for Suspected NSTEMI
Non-ST elevation myocardial infarction (NSTEMI) is a relatively complex type of myocardial infarction, characterized by chest pain symptoms and elevated troponin levels.
- Trial name
- SMART (NCT06689267)
- Testing
- computed tomography myocardial perfusion, Invasive Coronary Angiography
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Shanghai Zhongshan Hospital
Myocardial Infarction (MI), Heart Failure
Timing of Coronary Angiography in NSTEMI Complicated by Acute HF
Study objectives: To determine the optimal timing of coronary angiography (CAG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) complicated by acute decompensated heart failure (AHF).
- Trial name
- TIMING-AHF (NCT07002164)
- Testing
- Immediate coronary angiography, Delayed coronary angiography
- Where
- 20 sites in South Korea
- Volunteers
- 780 people
- Sponsor
- Chonnam National University Hospital
ST Segment Elevation Myocardial Infarction
Early Assessment of QFR in STEMI-II
The study intends to provide new data on whether the noval method using quantitative flow ratio could assess microvascular dysfunction based on the previous study EARLY-MYO-QFR-I.
- Trial name
- EARLYmyoQFR-II (NCT03910400)
- Testing
- Computation of quantitative flow ratio
- Where
- China
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Mi Q Wave, Coronary Artery Disease
New Time Clock for ST-elevation MI Based on Biochemical Myocardial Infarction Onset Time
ST segment elevation myocardial infarction (STEMI) is one of the leading causes of death across the world and immediate treatment with either thrombolytics or percutaneous coronary intervention (PCI) results in lower mortality.
- Trial name
- BIT-STEMI (NCT04389814)
- Testing
- Biochemical markers
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Tabba Heart Institute
ST-Elevation Myocardial Infarction
A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks
The main purpose of this research study is to try to improve the results of the standard treatment for heart attacks. Normally, heart attack patients get a fast dose and a slow dose of eptifibatide in the emergency room, shortly…
- Trial name
- IC TITAN (NCT00719914)
- Testing
- eptifibatide, normal saline
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Brigham and Women's Hospital
ST Elevation Myocardial Infarction, Fibrinolysis
Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis
This is a two-center, prospective, randomized, single-blind, investigator initiated, pharmacodynamic study of parallel design, carried out in 2 PCI-capable cardiology centers (Patras University Hospital and Konstantopoulio…
- Conditions
- ST Elevation Myocardial Infarction, Fibrinolysis, P2Y12 Inhibitor
- Trial name
- NCT01950416
- Testing
- Ticagrelor 180mg loading dose and 90mg bid maintenance dose, Clopidogrel 600mg loading dose and 150mg maintenance dose
- Where
- 2 sites in Greece
- Volunteers
- 56 people
- Sponsor
- University of Patras
Stable Angina, Unstable Angina
Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR
The purpose of this study is to determine whether preoperative loading dose atorvastatin can prevent perioperative myocardial infarction during angiography and main adverse cardiac events 1 month after operation in stable angina…
- Conditions
- Stable Angina, Unstable Angina, Acute Non-ST-segment Elevation Myocardial Infarction
- Trial name
- ARMYDA-IMR (NCT01761656)
- Testing
- loading dose atorvastatin, conventional dose atorvastatin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Central South University
Unstable Angina, NSTEMI
Dual Antiplatelet Therapy Tailored on the Extent of Platelet Inhibition
The purpose of this study is to evaluate the efficacy (reduction of major ischemic events at 6 and 12 months of follow-up) of a tailored clopidogrel therapy in patients with UA/NSTEMI undergoing PCI with stent implantation and…
- Trial name
- DANTE (NCT00774475)
- Testing
- comparison of different dosage of clopidogrel, doubled therapy
- Where
- Italy
- Volunteers
- 442 people
- Sponsor
- University of Florence
Acute Myocardial Infarction, Antiplatelet Therapy
Platelet Inhibition in the Acute Phase of STEMI
Background: Dual antithrombotic treatment with aspirin and clopidogrel is recommended in patients with ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
- Conditions
- Acute Myocardial Infarction, Antiplatelet Therapy, ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT01144819
- Where
- Denmark
- Volunteers
- 46 people
- Sponsor
- University of Aarhus
STEMI, Diabete Mellitus
Inflammatory and Hematological Indices in Diabetic STEMI Patients Undergoing Primary PCI
ST-segment Elevation Myocardial Infarction (STEMI) remains a major cause of mortality despite the adoption of Primary Percutaneous Coronary Intervention (PPCI) as the standard treatment.
- Trial name
- NCT07155395
- Volunteers
- 1,000 people
- Sponsor
- Assiut University
Unstable Anginas, Non ST Segment Elevation Myocardial Infarction
OCT Evaluation of Early Vascular Repair in Patients With Non ST Elevation Acute Coronary Syndrome (NSTE-ACS)
This is a prospective study of a new generation of drug-eluting stent in the treatment of non ST elevation acute coronary syndrome (NSTE-ACS).
- Trial name
- EXPECT (NCT04375319)
- Testing
- OCT
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Xuzhou Third People's Hospital
Coronary Artery Diseases
BIOFLOW III Satellite-Italy Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02028728
- Where
- 18 sites in Italy
- Volunteers
- 609 people
- Sponsor
- Biotronik Italia S.p.A.
Coronary Artery Disease
Pharmacological Effects of Crushing Prasugrel in STEMI Patients
Prasugrel has shown to be superior to clopidogrel, in adjunct to aspirin, in preventing recurrent ischemic events. Prasugrel is approved in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous…
- Trial name
- NCT02212028
- Testing
- prasugrel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of Florida
Acute ST-segment Elevation Myocardial Infarction
DCB Under the Guidance of OCT in STEMI
Acute ST segment elevation myocardial infarction (STEMI) has a high disability mortality rate, and timely reperfusion treatment can significantly reduce the mortality of patients.
- Trial name
- NCT05680051
- Testing
- Drug-eluting balloon, Drug-eluting stent
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Henan Institute of Cardiovascular Epidemiology